Compounded semaglutide is not an FDA-approved finished drug and is not reviewed by the FDA for safety, potency, or quality, so safety varies by pharmacy. The FDA has received adverse-event reports tied to compounded GLP-1s — many from dosing errors when patients draw doses from multi-dose vials themselves, and some from unregulated “semaglutide sodium/acetate” salt forms that are not the approved active ingredient.
A reputable, US-licensed compounding pharmacy (503A patient-specific or FDA-registered 503B) with clear dosing guidance and published sterility/potency testing meaningfully lowers the risk; unregulated, overseas, or “research peptide / not for human consumption” sources sharply raise it. Use our pharmacy safety checker to verify a source before you buy. As of July 2026.